Everyone’s 39 trillion of bacteria, our opportunity for tomorrow’s human microbiome therapeutics.

More informations

Passio Human Microbiome

We are moving beyond one speciality, focusing on human-centric development.

We are taking on industry challenges, being the only microbiome company developing microbiome therapeutics for GDM.

We are the team of collective talents dedicated to challenge status quo, encourage and sustain innovation.

Our focus areas:

Over 10 million people are living with IBD worldwide (over 3.4 million in Europe alone). It’s proven that the gut microbial unbalances are likely to contribute to disease severity. So that we are working on the solutions that will effectively balance the microbiome. Inflammatory Bowel Disease is a group of gastrointestinal inflammatory diseases which mainly comprises of Ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long terms chronic as well as severe inflammation in the gastrointestinal tract without any known cause.

Today the number of people with diabetes exceeded 422 million, it is forecasted that until 2035 this number will increase up to ½ billion. Globally, 10 times more people are living with diabetes than with HIV. Gut microbiota interacts with various host sensing and signalling pathways, leading to a modulation of the endocrine system, immune responses, nervous system activity, and hence, the predisposition to metabolic diseases. Gut microbiota dysbiosis drives and implies new therapeutic strategies for diabetes and related metabolic diseases. Based on that we are developing a new class of supportive treatment.

Although the microbial composition of the respiratory flora in COPD has been known through microbiome analyses, the involvement of the respiratory flora in the pathogenesis of the disease, and especially the role microorganisms considered non-pathogenic by culture-based microbiology, is practically unknown. We want to develop a treatment that will conserve the flora that acts as positive mutualist, as opposed to the respiratory pathogens that progressively replace it when COPD progresses to advanced disease.

Newest predictions said that 14 million people a year are diagnosed with cancer, but it is estimated that this number will increase to 19 million by 2025, 22 million by 2030 and 24 million by 2035. All scientific findings reveal alterations in the microbiota that may contribute to the aetiology of cancer. The extension of those findings may lead to strategies able to manipulate microbiota to support the treatment, prevent disease as well as to identify individuals at high risk.


Passio Human Microbiome, founded in 2016, is a comprehensive research center focused on the study of the microbiome and its impact on human health. We lead broad microbiome research across a range of therapeutic areas. We are the only microbiome company developing microbiome therapeutic for Gestational Diabetes Mellitus, GDM.


Our scientists combine science, translational medicine, and use powerful fields such as genomics, epigenomics, transcriptomics, proteomics, metabolomics and microfiometry, as well as bioinformatics to answer important questions about the microbiome. The aim is to use our strengths and the emerging possibilities of expanding the scope of research related to the microbiome. We are extremely proud of the fact that we conduct key research in the field of cancer therapy support, which results in Meliotic.


We develop non-invasive ways to monitor patients for signs of disease and precise methods to manipulate the microbiome to restore health. We do this by supporting translation studies designed to positively influence patients’ lives and collaborate on clinical trials to show how the microbiome affects human physiology, immune systems, metabolisms and disease progression. Supporting all our efforts is possible thanks to the multidisciplinary team, a specialized research center and careful data analysis.

The goal

Disrupt the life science business at the forefront of the burgeoning microbiome industry.

  • Explore the potential of the microbiome-host connection to create a differentiated product portfolio.


  • Commercialize our solutions to advance and scale our platform.


  • Adequately protect our intellectual property to secure our technology and products.


  • Actively collaborate to realize the potential of the microbiome.

We are constantly looking to explore new microbiome opportunities, improve our solutions and transform science into pipelines. Therefore, we are open to partnerships.